SCHEMBL25124429

SCHEMBL25124429

CCNc1ccc2oc(=O)n(C)c2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDH1 O75874 1/20 0.52
▸ KDM4E B2RXH2 2/20 0.47
▸ POLB P06746 2/20 0.44
▸ HSD17B10 Q99714 2/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ CASP1 P29466 1/20 0.44
▸ RECQL P46063 1/20 0.44
▸ CASP7 P55210 1/20 0.44
▸ PKM P14618 7/20 0.43
▸ LMNA P02545 2/20 0.43
▸ HTT P42858 1/20 0.43
▸ MEN1 O00255 3/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ GFER P55789 1/20 0.41
▸ DDB1 Q16531 1/20 0.41
▸ CRBN Q96SW2 1/20 0.41
▸ MAPK1 P28482 2/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ JAK1 P23458 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18171805 0.83 ALDH1A1 (0.50) KDM4EPOLBHSD17B10ALDH1A1HPGD
SCHEMBL21646503 0.82 KDM4E (0.47) IDH1KDM4EPOLBALDH1A1HPGD
SCHEMBL3524747 0.78 MEN1 (0.45) IDH1KDM4EPOLBALDH1A1HPGD
SCHEMBL18171780 0.76 MIF (0.66) POLBALDH1A1MEN1KMT2ATP53
SCHEMBL8218368 0.76 MIF (0.53) KDM4EALDH1A1HPGDPKMMEN1
SCHEMBL26280246 0.75 KDM4E (0.44) IDH1KDM4EPOLBHSD17B10ALDH1A1
SCHEMBL434086 0.73 MIF (0.54) POLBALDH1A1PKMLMNAMEN1
SCHEMBL6840918 0.72 KDM4E (0.50) IDH1KDM4EPOLBHSD17B10ALDH1A1
SCHEMBL5544722 0.71 IDO1 (0.57) IDH1ALDH1A1PKMTP53
SCHEMBL3330251 0.71 PKM (0.49) KDM4EPOLBALDH1A1HPGDPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230109839-A1 THERAPEUTIC AGENT FOR TAUOPATHIES Sumitomo Pharma Co., Ltd. (JP) 2023-04-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230109839-A1 THERAPEUTIC AGENT FOR TAUOPATHIES MAPT, PSEN1, PSEN2 IDH1 2427/4885KDM4E 3621/4885POLB 4130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback